AI-Designed Peptide Enters Late-Stage Infection Trial

Peptilogics advances zaloganan into Phase 2/3 with $120mn in funding to tackle biofilm-related joint infections 

20 Feb 2026

Peptilogics has begun a pivotal Phase 2/3 clinical trial for zaloganan, an experimental peptide therapy designed to treat prosthetic joint infections after hip and knee replacements. The move follows a $78mn financing round that brings the company’s total funding to about $120mn, including grants, signalling growing investor confidence in its AI-driven peptide design platform.

Prosthetic joint infections affect tens of thousands of patients in the US each year and remain among the most difficult surgical complications to manage. The infections persist because bacteria form biofilms, protective layers that shield them from antibiotics, often requiring repeat operations and extended hospital stays.

Zaloganan is intended to target these biofilms directly. Developed using computational tools and AI-assisted peptide engineering, the therapy is administered locally during standard surgical cleaning procedures to attack infection at its source rather than relying only on systemic antibiotics.

Early trial data showed encouraging results. In an initial study, 13 of 14 treated patients remained infection-free after one year. Although the sample size was small, the findings were sufficient to secure Fast Track, Orphan Drug, and Qualified Infectious Disease Product designations from US regulators. The new Phase 2/3 study will enrol roughly 240 patients.

The trial comes as joint replacement procedures continue to rise with ageing populations, increasing both infection risk and healthcare costs. Hospitals face pressure to limit surgical complications and control spending, and a more effective treatment could ease those strains.

Investors in Peptilogics include Presight Capital, Thiel Bio, Founders Fund, AMR Action Fund, Narya Capital, and Beyond Ventures. The company’s approach reflects broader momentum in computational biotechnology, where machine learning tools are used to design targeted therapies more efficiently.

If the larger trial confirms earlier results, zaloganan could represent a significant advance in infection control for orthopedic surgery and provide further evidence of the role of AI in drug development.